NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Health Technology Appraisal

Review of NICE Technology Appraisal guidance no. 86, Imatinib for gastrointestinal stromal tumours

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors Novartis (imatinib) Patient/carer groups Afiya Trust Age Concern England Beating Bowel Cancer Black Health Agency Bowel Cancer UK CANCERactive Cancerbackup Cancer Black Care Cancer Equality Cancer Voices Chinese National Healthy Living Centre Confederation of Indian Organisations CORE – The Digestive Disorders Foundation Counsel and Care Equalities National Council GIST Support UK Helen Rollason Heal Cancer Charity Help the Aged Lynn's Bowel Cancer Campaign Macmillan Cancer Support Maggie's Centres Marie Curie Cancer Care Muslim Council of Great Britain Muslim Health Network National Cancer Alliance National Council for Palliative Care Ochre Oesophageal Patients Association Pelican Cancer Foundation	 General Age Concern Cymru Board of Community Health Councils in Wales British National Formulary Cancer Care Cymru Department of Health, Social Services and Public Safety for Northern Ireland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Public Health Service for Wales NHS Alliance NHS Confederation NHS Purchasing and Supply Agency NHS Quality Improvement Scotland Scottish Medicines Consortium Comparator manufacturer(s) Pfizer (sunitinib) Relevant research groups Institute of Cancer Research Institute National Cancer Research Network National Institute for Health Research Policy Research Institute on Ageing and Ethnicity Research Institute for the Care of Older People United Kingdom Clinical Research Network

National Institute for Health and Clinical Excellence

Matrix for the review of NICE Technology Appraisal guidance no. 86, Imatinib for gastrointestinal stromal tumours

Issue date: June 2009

Consultees Commentators (no right to submit or appeal) Rarer Cancers Forum Assessment Group Sarcoma UK Assessment Group tbc S.C.A.N National Institute for Health Research South Asian Health Foundation Health Technology Assessment Specialised Healthcare Alliance Programme Sue Ryder Care **Tenovus Cancer Information Centre Associated Guideline Groups Tummy Trouble** National Collaborating Centre for Cancer Professional groups Association of Cancer Physicians Associated Public Health Groups British Association for Services to tbc the Elderly **British Geriatric Society British Oncological Association** British Psychosocial Oncology Society British Society of Gastroenterology Cancer Networks Pharmacists Forum Cancer Research UK Royal College of General **Practitioners** Royal College of Nursing Royal College of Pathologists Royal College of Physicians, Medical Oncology Joint Special Committee Royal College of Radiologists Royal Pharmaceutical Society Royal Society of Medicine -Intellectual Disabilities Forum United Kingdom Clinical Pharmacy Association United Kingdom Oncology Nursing Society Others Cumbria PCT Department of Health East Sussex Downs and Weald PCT

Welsh Assembly Government

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Assessment team

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology

National Institute for Health and Clinical Excellence Matrix for the review of NICE Technology Appraisal guidance no. 86, Imatinib for gastrointestinal stromal tumours

Issue date: June 2009

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.

(a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).